Osteoarthritis

Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial

Lancet RheumatolPublished Randomised controlled trial

Primary result · OMERACT-OARSI respondersResult — go to the resultOdds ratio 1.01 95% CI 0.63–1.62

Authors' conclusion

Occupational therapist-led care for hand osteoarthritis is non-inferior to rheumatologist-led care in terms of efficacy and safety.

Study context

Population
Participants with hand OA aged 18 years or older, two hospitals in Norway302 (80.7%) women
Participants
374 participants
Comparison
Occupational therapist-led care vs rheumatologist-led care
  • Occupational therapist-led caren = 188
  • Rheumatologist-led caren = 186reference
Primary endpoint
Response to treatment according to the OMERACT-OARSI criteria
Follow-up
6 months
Methodological detailsopen-label, multicentre, non-inferiority, stratified by centre
  • Open-label
  • Multicentre
  • Non-inferiority
  • Stratified by centre

Primary result

OMERACT-OARSI responders

Odds ratio

1.01

95% CI 0.63–1.62

Events by treatment group

Occupational therapist-led carevs Rheumatologist-led care
OR 1.01 (95% CI 0.63–1.62)

As reported in the abstract

Further findings

Cost-utility analysis (Norwegian health-care system perspective)

Occupational therapist-led care cost-effective up to a willingness to pay per quality-adjusted life-year of
£23 255

Safety

No severe adverse events were recorded

Original publication

Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial. Lancet Rheumatol. Published 10 June 2025. doi:10.1016/s2665-9913(25)00040-2

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.